TransMedics Group Inc. (NASDAQ: TMDX) stock jumped 0.29% on Wednesday to $71.60 against a previous-day closing price of $71.39. With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.61 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $71.72 whereas the lowest price it dropped to was $69.38. The 52-week range on TMDX shows that it touched its highest point at $90.15 and its lowest point at $24.01 during that stretch. It currently has a 1-year price target of $88.00. Beta for the stock currently stands at 1.45.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TMDX was down-trending over the past week, with a drop of -4.99%, but this was down by -13.85% over a month. Three-month performance dropped to -7.97% while six-month performance rose 24.05%. The stock gained 155.62% in the past year, while it has gained 16.01% so far this year. A look at the trailing 12-month EPS for TMDX yields -0.95 with Next year EPS estimates of 0.11. For the next quarter, that number is -0.14. This implies an EPS growth rate of 23.40% for this year and 123.40% for next year.
Float and Shares Shorts:
At present, 32.26 million TMDX shares are outstanding with a float of 30.68 million shares on hand for trading. On Apr 27, 2023, short shares totaled 2.44 million, which was 7.49% higher than short shares on Mar 30, 2023. In addition to Dr. Waleed H. Hassanein M.D. as the firm’s Founder, Pres, CEO & Director, Mr. Stephen Gordon serves as its CFO, Treasurer & Sec.
Institutional Ownership:
Through their ownership of 93.34% of TMDX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 56.31% of TMDX, in contrast to 38.03% held by mutual funds. Shares owned by individuals account for 20.10%. As the largest shareholder in TMDX with 10.07% of the stake, Fidelity Management & Research Co holds 3,243,718 shares worth 3,243,718. A second-largest stockholder of TMDX, BlackRock Fund Advisors, holds 2,017,192 shares, controlling over 6.27% of the firm’s shares. Lord, Abbett & Co. LLC is the third largest shareholder in TMDX, holding 1,854,083 shares or 5.76% stake. With a 3.65% stake in TMDX, the Delaware Small Cap Core Fund is the largest stakeholder. A total of 1,175,927 shares are owned by the mutual fund manager. The Fidelity Advisor Series I -Growth, which owns about 3.29% of TMDX stock, is the second-largest Mutual Fund holder. It holds 1,058,917 shares valued at 83.76 million. Vanguard Total Stock Market ETF holds 2.93% of the stake in TMDX, owning 941,658 shares worth 74.49 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, TMDX reported revenue of $20.52M and operating income of -$9.74M. The EBITDA in the recently reported quarter was -$10.53M and diluted EPS was -$0.41.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TMDX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With TMDX analysts setting a high price target of $99.00 and a low target of $81.00, the average target price over the next 12 months is $90.20. Based on these targets, TMDX could surge 38.27% to reach the target high and rise by 13.13% to reach the target low. Reaching the average price target will result in a growth of 25.98% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded TMDX stock several times over the past three months with 7 Buys and 18 Sells. In these transactions, 461,485 shares were bought while 61,934 shares were sold. The number of buy transactions has increased to 72 while that of sell transactions has risen to 117 over the past year. The total number of shares bought during that period was 860,958 while 645,788 shares were sold.
